Neuland Laboratories share news and announcements
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Last close ₹18,865.00down ₹70.00 (0.37%)BSE ₹18,924.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹18,935.00.
52-week range of traded prices to 23 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹24,204 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 48.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 12.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 53,34748.3% delivered
Neuland Laboratories shareholder meetings
72 filed, newest first. Page 2 of 2.
Feb 2016
Jan 2016
Sep 2015
Aug 2015
Jul 2015
Jun 2015
Jul 2014
Jun 2014
May 2014
13 May · Meeting
Register of members and share transfer books of the company will remain closed June 18, 2014 to June 24, 2014 (both days inclusive) for the purpose of Dividend and Annual General Meeting of the Company to be held on June 24, 2014.
Aug 2013
Sep 2012
Aug 2012
Jul 2012
6 Jul · Meeting
Annual General Meeting of the Company will be held on August 10, 2012.
Jun 2012
Aug 2011
8 Aug · Meeting
Shareholders at the Annual General Meeting of the Company held on August 05, 2011 have approved the following business : (1) Appointed Mr. Will Mitchell, as Director retiring by rotation; (2) Appointed Mr. S.B. Budhiraja, as Director retiring by rotation; (3) Appointed M/s. K S Aiyar & Co. as Auditors for the year ending March 31, 2012; (4) Approved Dr. Christopher M. Cimarusti to hold an office or place of profit for a period of 5 years; (5) Payment of commission to Non Executive Directors for a period of 5 years commencing April 01, 2011 @ 1% of the net profit of the Company.
Jun 2011
28 Jun · Meeting
Annual General Meeting of the company will be held on August 05, 2011. Further the Register of members and share transfer books of the company will remain closed from August 02, 2011 to August 05, 2011 (both days inclusive) for the purpose of the Annual General Meeting.
Aug 2010
2 Aug · Meeting
Shareholders at the Annual General Meeting of the Company held on July 29, 2010 passed the following resolutions with requisite majority : (1) Approved monthly remuneration not exceeding Rs. 4,00,000/- to Dr. D.R. Rao as Chairman and Managing Director for a period of 3 years w.e.f. April 01, 2009; (2) Approved monthly remuneration not exceeding Rs. 4,00,000/- to Mr. D. Sucheth Rao, as Whole-time Director and CEO for a period of 3 years w.e.f. April 01, 2009; (3) Approved monthly remuneration not exceeding Rs. 3,50,000/- to Mr. D. Saharsh Rao, as Whole-time Director and President-Contract Research for a period of 3 years w.e.f. June 01, 2009.
Jul 2009
20 Jul · Meeting
Outcome of Annual General of the Company held on July 18, 2009 passed the following resolutions with requisite majority: (1) Appointed Mr.S. B. Budhiraja, as Director retiring by rotation. (2) Appointed Mr. G.V.K. Rama Rao, as Director retiring by rotation. (3) Declared dividend @ Rs.3.50/- per equity share for the financial year 2008-09.(4) Appointed M/s.K.S. Aiyar & Co., as Auditors for the year ending March 31, 2010 (4) Appointed Mr. D. Saharsh Rao as Whole Time Director of the Company designated as President-Contract Research for the period of three years with effects from June 1, 2009.3 Jul · Meeting
Notice of the Annual General Meeting of the Members of the company to be held on July 18, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
29 Jun · Meeting
Annual General Meeting of the Shareholders of the Company will be held on July 18, 2009.